Education

FDA Approves First Therapy for Rare Form of Osteomalacia

FDA Approves First Therapy for Rare Form of Osteomalacia
The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Md., on Nov. 4, 2009. Jason Reed/AP-File
Venus Upadhayaya
|Updated:
The Food and Drug Administration (FDA) has approved an injectable drug for a rare illness that causes low phosphate blood levels and bone softening, according to a notice on June 18.

FDA approved Crysvita (burosumab-twza), an injectable drug to treat tumor-induced osteomalacia (TIO) for patients above two years.

Venus Upadhayaya
Venus Upadhayaya
Reporter
Venus Upadhayaya reports on India, China, and the Global South. Her traditional area of expertise is in Indian and South Asian geopolitics. Community media, sustainable development, and leadership remain her other areas of interest.
twitter
Related Topics